Genitourinary System Carcinoma — Trials

Genitourinary System Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

4,916 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1,498
Recruiting: 782
Ph III recruiting: 85
Growth YoY: +17.8%
Industry share: 27%
Top sponsor: National Cancer Institute (NCI)
Termination share: 37.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (758)

clinicaltrialsPublishedShowing 501–502 of 502 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00001683	A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer	completed	Phase 1	35	National Cancer Institute (NCI)NIH	1	Mar 4, 2008	clinicaltrials
NCT00056173	Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma	completed	Phase 1 / Phase 2	43	Aptose Biosciences Inc.INDUSTRY	1	Jan 7, 2008	clinicaltrials